Neuronix has developed a patented technology that uses Transcranial Magnetic Stimulation (TMS) interlaced with Cognitive Training (CgT).
Prior to treatment, you will undergo a Magnetic Resonance Imaging (MRI) scan that will identify regions in your brain that have been affected by AD. Using the MRI scan, the Neuronix team marks the precise location of these brain regions and registers their spatial coordinates. These coordinates are then uploaded into the neuroADTM Therapy System.
Using a proprietary infrared optical Navigation Unit, the TMS applicator is placed against the scalp so that the selected brain region can be precisely stimulated. The applicator is made of a coil which emits a focused magnetic field that strengthens the signal transmission and chemical bonds between the neurons in the brain. This strengthening process is hypothesized to promote Long-term potentiation (LTP) – the primary cellular mechanism responsible for memory and cognitive functions.
TMS has been used in medical settings since 1985 and has an extremely high safety profile. It has been beneficial in the treatment of depression, obsessive-compulsive disorder (OCD), posttraumatic stress disorder, migraines and more.
Neuronix technology uses cognitive training (CgT) exercises concurrently with the TMS. The exercises are designed to further stimulate the areas targeted by the TMS. The exercises include a variety of tasks ranging from language to spatial skills. The CgT software adjusts the level of difficultly to match the cognitive level of the patient.
The purpose of the cognitive training is to improve the functionality of the neuron connections that are being stimulated and reinforce the brain’s cognitive reserve, or the brain’s ability to function in the presence of brain pathology.
While TMS and Cognitive training have each been tested individually in various studies, neither have been shown to repeatedly yield long lasting or unequivocal results. The TMS alone has an effect that lasts only several minutes, and the cognitive training has not proven itself as effective in treating patients with AD. Neuronix has discovered that only by combining the technologies, measurable lasting improvements can be achieved. Click here to review our clinical evidence.